Aravive Biologics   Report issue

For profit Phase 1 Phase 2 Phase 3
Founded: Houston TX United States (2016)

Organization Overview

First Clinical Trial
2018
NCT03401528
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2023

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

Aravive Biologics | Aravive Biologics Inc | Aravive Biologics, Inc. | Aravive, Inc.

Active Ingredients

Drugs in Phase 3 Trials (4)

Key: Aravive Biologics (2) Acquired (2)

avb-s6-500 (9 trials)

paclitaxel (taxol) (5 trials)

somatropin (protropin) (1 trial)

somavaratan (8 trials)

Drugs in Phase 2 Trials (4)

avelumab (bavencio) (1 trial)

cabozantinib (cometriq) (1 trial)

doxorubicin (Doxil) (1 trial)

gemcitabine (gemzar) (1 trial)

Drugs in Phase 1 Trials (1)

carboplatin (paraplatin) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Carcinoma (Phase 2)

Carcinoma, Ovarian Epithelial (Phase 2)

Carcinoma, Renal Cell (Phase 2)

Carcinoma, Transitional Cell (Phase 2)

Fallopian Tube Neoplasms (Phase 2)

Glomerulonephritis, IGA (Phase 2)

Kidney Diseases (Phase 2)

Ovarian Neoplasms (Phase 2)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 17
  • # of Trial APIs: 9